M&T Bank Corp Trims Holdings in Corteva, Inc. $CTVA

Key Points

• M&T Bank Corp trimmed its position in Corteva by 2.9% in Q4, selling 55,322 shares and now holds 1,850,532 shares valued at $124,042,000 (about 0.27% of the company).
• Corteva reported quarterly EPS of $0.22 (in line with estimates) but revenue of $3.91 billion missed the $4.23 billion consensus; it set FY2026 guidance of $3.45–$3.70 EPS and has an average analyst target of $86.38 (Moderate Buy).
• The company declared a quarterly dividend of $0.18 (annualized $0.72) with an ex-dividend/record date of June 1 and payment on June 15, implying a yield of about 0.9%.

M&T Bank Corp trimmed its position in Corteva, Inc. (NYSE:CTVA - Free Report) by 2.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,850,532 shares of the company's stock after selling 55,322 shares during the quarter. M&T Bank Corp owned about 0.27% of Corteva worth $124,042,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Activest Wealth Management raised its position in Corteva by 118.3% during the third quarter. Activest Wealth Management now owns 369 shares of the company's stock valued at $25,000 after acquiring an additional 200 shares in the last quarter. JPL Wealth Management LLC acquired a new stake in Corteva in the third quarter valued at approximately $25,000. True Wealth Design LLC grew its holdings in Corteva by 209.5% in the third quarter. True Wealth Design LLC now owns 390 shares of the company's stock valued at $26,000 after purchasing an additional 264 shares during the period. Redmont Wealth Advisors LLC acquired a new stake in Corteva in the third quarter valued at approximately $29,000. Finally, Jackson Grant Investment Advisers Inc. grew its holdings in Corteva by 90.6% in the third quarter. Jackson Grant Investment Advisers Inc. now owns 448 shares of the company's stock valued at $30,000 after purchasing an additional 213 shares during the period. 81.54% of the stock is currently owned by hedge funds and other institutional investors.

Corteva Stock Performance

Shares of NYSE:CTVA opened at $80.97 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.96. The business's 50 day moving average price is $80.39 and its 200-day moving average price is $72.18. The firm has a market capitalization of $54.36 billion, a PE ratio of 51.24, a P/E/G ratio of 2.77 and a beta of 0.59. Corteva, Inc. has a 1 year low of $60.53 and a 1 year high of $85.63.

Corteva (NYSE:CTVA - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.22. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The business's revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 earnings per share. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. As a group, equities research analysts expect that Corteva, Inc. will post 3.62 earnings per share for the current fiscal year.

Corteva Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 15th. Stockholders of record on Monday, June 1st will be paid a $0.18 dividend. The ex-dividend date of this dividend is Monday, June 1st. This represents a $0.72 dividend on an annualized basis and a dividend yield of 0.9%. Corteva's payout ratio is currently 45.57%.

Analysts Set New Price Targets

Several brokerages have commented on CTVA. Mizuho raised their price objective on Corteva from $82.00 to $94.00 and gave the company an "outperform" rating in a report on Wednesday, April 15th. Berenberg Bank raised their price objective on Corteva from $68.00 to $78.00 and gave the company a "hold" rating in a report on Thursday, March 26th. Citigroup raised their price objective on Corteva from $74.00 to $80.00 and gave the company a "neutral" rating in a report on Thursday, February 5th. Rothschild & Co Redburn raised their price objective on Corteva from $80.00 to $90.00 and gave the company a "neutral" rating in a report on Wednesday, April 29th. Finally, Wolfe Research raised their price objective on Corteva from $81.00 to $86.00 and gave the company an "outperform" rating in a report on Thursday, February 5th. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat, Corteva presently has an average rating of "Moderate Buy" and an average target price of $86.38.

Insider Activity

In other news, insider Brian Titus sold 8,311 shares of Corteva stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the sale, the insider directly owned 8,090 shares of the company's stock, valued at $619,289.50. The trade was a 50.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.15% of the stock is owned by corporate insiders.

Corteva Profile

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.